Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Campylobacter | Research article

Bacteraemia, antimicrobial susceptibility and treatment among Campylobacter-associated hospitalisations in the Australian Capital Territory: a review

Authors: Cameron R. M. Moffatt, Karina J. Kennedy, Ben O’Neill, Linda Selvey, Martyn D. Kirk

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Campylobacter spp. cause mostly self-limiting enterocolitis, although a significant proportion of cases require hospitalisation highlighting potential for severe disease. Among people admitted, blood culture specimens are frequently collected and antibiotic treatment is initiated. We sought to understand clinical and host factors associated with bacteraemia, antibiotic treatment and isolate non-susceptibility among Campylobacter-associated hospitalisations.

Methods

Using linked hospital microbiology and administrative data we identified and reviewed Campylobacter-associated hospitalisations between 2004 and 2013. We calculated population-level incidence for Campylobacter bacteraemia and used logistic regression to examine factors associated with bacteraemia, antibiotic treatment and isolate non-susceptibility among Campylobacter-associated hospitalisations.

Results

Among 685 Campylobacter-associated hospitalisations, we identified 25 admissions for bacteraemia, an estimated incidence of 0.71 cases per 100,000 population per year. Around half of hospitalisations (333/685) had blood culturing performed. Factors associated with bacteraemia included underlying liver disease (aOR 48.89, 95% CI 7.03–340.22, p < 0.001), Haematology unit admission (aOR 14.67, 95% CI 2.99–72.07, p = 0.001) and age 70–79 years (aOR 4.93, 95% CI 1.57–15.49). Approximately one-third (219/685) of admissions received antibiotics with treatment rates increasing significantly over time (p < 0.05). Factors associated with antibiotic treatment included Gastroenterology unit admission (aOR 3.75, 95% CI 1.95–7.20, p < 0.001), having blood cultures taken (aOR 2.76, 95% CI 1.79–4.26, p < 0.001) and age 40–49 years (aOR 2.34, 95% CI 1.14–4.79, p = 0.02). Non-susceptibility of isolates to standard antimicrobials increased significantly over time (p = 0.01) and was associated with overseas travel (aOR 11.80 95% CI 3.18–43.83, p < 0.001) and negatively associated with tachycardia (aOR 0.48, 95%CI 0.26–0.88, p = 0.02), suggesting a healthy traveller effect.

Conclusions

Campylobacter infections result in considerable hospital burden. Among those admitted to hospital, an interplay of factors involving clinical presentation, presence of underlying comorbidities, complications and increasing age influence how a case is investigated and managed.
Literature
2.
go back to reference Zollner-Schwetz I, Krause R. Therapy of acute gastroenteritis: role of antibiotics. Clin Microbiol Infect. 2015;21(8):744–9.PubMedCrossRef Zollner-Schwetz I, Krause R. Therapy of acute gastroenteritis: role of antibiotics. Clin Microbiol Infect. 2015;21(8):744–9.PubMedCrossRef
3.
go back to reference Nielsen H, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect. 2010;16(1):57–61.PubMedCrossRef Nielsen H, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect. 2010;16(1):57–61.PubMedCrossRef
4.
go back to reference Linsenmeyer K, et al. Culture if spikes? Indications and yield of blood cultures in hospitalized medical patients. J Hosp Med. 2016;11(5):336–40.PubMedCrossRef Linsenmeyer K, et al. Culture if spikes? Indications and yield of blood cultures in hospitalized medical patients. J Hosp Med. 2016;11(5):336–40.PubMedCrossRef
5.
go back to reference Sproston EL, Wimalarathna HML, Sheppard SK. Trends in fluoroquinolone resistance in Campylobacter. Microb Genom. 2018;4(8):1. Sproston EL, Wimalarathna HML, Sheppard SK. Trends in fluoroquinolone resistance in Campylobacter. Microb Genom. 2018;4(8):1.
7.
go back to reference Clinical Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing: Twenty-third informational supplement. CLSI document M100-S23. 2013, Clinical and Laboratory Standards Institute Wayne, PA. Clinical Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing: Twenty-third informational supplement. CLSI document M100-S23. 2013, Clinical and Laboratory Standards Institute Wayne, PA.
8.
go back to reference Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef
9.
go back to reference Australian Bureau of Statistics, Australian Historical Population Statistics; 2014. 2014, Commonwealth of Australia: Canberra. Australian Bureau of Statistics, Australian Historical Population Statistics; 2014. 2014, Commonwealth of Australia: Canberra.
10.
go back to reference Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6.PubMedCrossRef Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6.PubMedCrossRef
11.
go back to reference Fernandez-Cruz A, et al. Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Med (Baltim). 2010;89(5):319–30.CrossRef Fernandez-Cruz A, et al. Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Med (Baltim). 2010;89(5):319–30.CrossRef
12.
go back to reference Schonheyder HC, Sogaard P, Frederiksen W. A survey of Campylobacter bacteremia in three Danish counties, 1989 to 1994. Scand J Infect Dis. 1995;27(2):145–8.PubMedCrossRef Schonheyder HC, Sogaard P, Frederiksen W. A survey of Campylobacter bacteremia in three Danish counties, 1989 to 1994. Scand J Infect Dis. 1995;27(2):145–8.PubMedCrossRef
13.
go back to reference Harvala H, et al. Increased number of Campylobacter bacteraemia cases in Sweden, 2014. Clin Microbiol Infect. 2016;22(4):391–3.PubMedCrossRef Harvala H, et al. Increased number of Campylobacter bacteraemia cases in Sweden, 2014. Clin Microbiol Infect. 2016;22(4):391–3.PubMedCrossRef
14.
go back to reference Moffatt CR, et al. The campylobacteriosis conundrum - examining the incidence of infection with Campylobacter sp. in Australia, 1998–2013. Epidemiol Infect. 2017;145(4):839–47.PubMedCrossRef Moffatt CR, et al. The campylobacteriosis conundrum - examining the incidence of infection with Campylobacter sp. in Australia, 1998–2013. Epidemiol Infect. 2017;145(4):839–47.PubMedCrossRef
15.
go back to reference Coburn B, et al. Does this adult patient with suspected bacteremia require blood cultures? JAMA. 2012;308(5):502–11.PubMedCrossRef Coburn B, et al. Does this adult patient with suspected bacteremia require blood cultures? JAMA. 2012;308(5):502–11.PubMedCrossRef
16.
go back to reference Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. QJM. 1996;89(7):515–22.PubMedCrossRef Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. QJM. 1996;89(7):515–22.PubMedCrossRef
17.
go back to reference James MT, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168(21):2333–9.PubMedCrossRef James MT, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168(21):2333–9.PubMedCrossRef
18.
go back to reference Foley RN. Infections in patients with chronic kidney disease. Infect Dis Clin North Am. 2007;21(3):659–72.PubMedCrossRef Foley RN. Infections in patients with chronic kidney disease. Infect Dis Clin North Am. 2007;21(3):659–72.PubMedCrossRef
19.
go back to reference Eliakim-Raz N, Bates DW, Leibovici L. Predicting bacteraemia in validated models–a systematic review. Clin Microbiol Infect. 2015;21(4):295–301.PubMedCrossRef Eliakim-Raz N, Bates DW, Leibovici L. Predicting bacteraemia in validated models–a systematic review. Clin Microbiol Infect. 2015;21(4):295–301.PubMedCrossRef
20.
go back to reference Louwen R, et al. Campylobacter bacteremia: a rare and under-reported event? Eur J Microbiol Immunol (Bp). 2012;2(1):76–87.CrossRef Louwen R, et al. Campylobacter bacteremia: a rare and under-reported event? Eur J Microbiol Immunol (Bp). 2012;2(1):76–87.CrossRef
21.
go back to reference Hussein K, et al. Campylobacter bacteraemia: 16 years of experience in a single centre. Infect Dis (Lond). 2016;48(11–12):796–9.CrossRef Hussein K, et al. Campylobacter bacteraemia: 16 years of experience in a single centre. Infect Dis (Lond). 2016;48(11–12):796–9.CrossRef
22.
go back to reference Pacanowski J, et al. Campylobacter bacteremia: clinical features and factors associated with fatal outcome. Clin Infect Dis. 2008;47(6):790–6.PubMedCrossRef Pacanowski J, et al. Campylobacter bacteremia: clinical features and factors associated with fatal outcome. Clin Infect Dis. 2008;47(6):790–6.PubMedCrossRef
24.
go back to reference Pigrau C, et al. Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns. Clin Infect Dis. 1997;25(6):1414–20.PubMedCrossRef Pigrau C, et al. Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns. Clin Infect Dis. 1997;25(6):1414–20.PubMedCrossRef
25.
go back to reference Cody AJ, et al. Ciprofloxacin-resistant campylobacteriosis in the UK. Lancet. 2010; 376(9757):1987. Cody AJ, et al. Ciprofloxacin-resistant campylobacteriosis in the UK. Lancet. 2010; 376(9757):1987.
26.
go back to reference Post A, et al. Antibiotic susceptibility profiles among Campylobacter isolates obtained from international travelers between 2007 and 2014. Eur J Clin Microbiol Infect Dis. 2017;36(11):2101–7.PubMedPubMedCentralCrossRef Post A, et al. Antibiotic susceptibility profiles among Campylobacter isolates obtained from international travelers between 2007 and 2014. Eur J Clin Microbiol Infect Dis. 2017;36(11):2101–7.PubMedPubMedCentralCrossRef
27.
go back to reference Geissler AL, et al. Increasing Campylobacter infections, outbreaks, and antimicrobial resistance in the United States, 2004–2012. Clin Infect Dis. 2017;65(10):1624–31.PubMedCrossRef Geissler AL, et al. Increasing Campylobacter infections, outbreaks, and antimicrobial resistance in the United States, 2004–2012. Clin Infect Dis. 2017;65(10):1624–31.PubMedCrossRef
28.
go back to reference European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC). EU Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013. EFSA J. 2015;13(2):4036. European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC). EU Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013. EFSA J. 2015;13(2):4036.
29.
go back to reference Unicomb LE, et al. Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. Clin Infect Dis. 2006;42(10):1368–74.PubMedCrossRef Unicomb LE, et al. Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. Clin Infect Dis. 2006;42(10):1368–74.PubMedCrossRef
31.
go back to reference Devi A, et al. Antimicrobial susceptibility of clinical isolates of Campylobacter jejuni from New South Wales, Australia. J Glob Antimicrob Resist. 2019;16:76–80.PubMedCrossRef Devi A, et al. Antimicrobial susceptibility of clinical isolates of Campylobacter jejuni from New South Wales, Australia. J Glob Antimicrob Resist. 2019;16:76–80.PubMedCrossRef
32.
go back to reference Wallace R, et al., Status of antimicrobial resistance in clinical isolates of Campylobacter jejuni and Campylobacter jejuni in Australia. J Clin Microbiol. 2019. Wallace R, et al., Status of antimicrobial resistance in clinical isolates of Campylobacter jejuni and Campylobacter jejuni in Australia. J Clin Microbiol. 2019.
33.
go back to reference Ricotta EE, et al. Epidemiology and antimicrobial resistance of international travel-associated Campylobacter infections in the United States, 2005–2011. Am J Public Health. 2014;104(7):e108-14.PubMedCrossRef Ricotta EE, et al. Epidemiology and antimicrobial resistance of international travel-associated Campylobacter infections in the United States, 2005–2011. Am J Public Health. 2014;104(7):e108-14.PubMedCrossRef
34.
go back to reference Hoge CW, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26(2):341–5.PubMedCrossRef Hoge CW, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26(2):341–5.PubMedCrossRef
36.
go back to reference Arsenault J, et al. Do patients with recurrent episodes of campylobacteriosis differ from those with a single disease event? BMC Public Health. 2011;11:32.PubMedPubMedCentralCrossRef Arsenault J, et al. Do patients with recurrent episodes of campylobacteriosis differ from those with a single disease event? BMC Public Health. 2011;11:32.PubMedPubMedCentralCrossRef
37.
go back to reference Marcotte H, Hammarström L. Immunodeficiencies: significance for gastrointestinal disease, in Viral Gastroenteritis. Elsevier; 2016. pp. 47–71. Marcotte H, Hammarström L. Immunodeficiencies: significance for gastrointestinal disease, in Viral Gastroenteritis. Elsevier; 2016. pp. 47–71.
38.
go back to reference Wassenaar TM, Kist M, de Jong A. Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections. Int J Antimicrob Agents. 2007;30(3):195–201.PubMedCrossRef Wassenaar TM, Kist M, de Jong A. Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections. Int J Antimicrob Agents. 2007;30(3):195–201.PubMedCrossRef
41.
go back to reference Helms M, Simonsen J, Molbak K. Foodborne bacterial infection and hospitalization: a registry-based study. Clin Infect Dis. 2006;42(4):498–506.PubMedCrossRef Helms M, Simonsen J, Molbak K. Foodborne bacterial infection and hospitalization: a registry-based study. Clin Infect Dis. 2006;42(4):498–506.PubMedCrossRef
42.
go back to reference Turnidge JD, et al. Antimicrobial use in Australian hospitals: how much and how appropriate? Med J Aust. 2016;205(10):S16–20.PubMed Turnidge JD, et al. Antimicrobial use in Australian hospitals: how much and how appropriate? Med J Aust. 2016;205(10):S16–20.PubMed
43.
go back to reference National Institute for Health Care Excellence (NICE) and Public Health England (PHE), Summary of antimicrobial prescribing guidance-managing common infections; 2019. National Institute for Health Care Excellence (NICE) and Public Health England (PHE), Summary of antimicrobial prescribing guidance-managing common infections; 2019.
44.
go back to reference Shane AL, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017;65(12):1963–73.PubMedPubMedCentralCrossRef Shane AL, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017;65(12):1963–73.PubMedPubMedCentralCrossRef
46.
go back to reference Gillespie IA, et al. Investigating vomiting and/or bloody diarrhoea in Campylobacter jejuni infection. J Med Microbiol. 2006;55(Pt 6):741–6.PubMedCrossRef Gillespie IA, et al. Investigating vomiting and/or bloody diarrhoea in Campylobacter jejuni infection. J Med Microbiol. 2006;55(Pt 6):741–6.PubMedCrossRef
47.
go back to reference Shapiro NI, et al. Who needs a blood culture? A prospectively derived and validated prediction rule. J Emerg Med. 2008;35(3):255–64.PubMedCrossRef Shapiro NI, et al. Who needs a blood culture? A prospectively derived and validated prediction rule. J Emerg Med. 2008;35(3):255–64.PubMedCrossRef
48.
go back to reference Feodoroff B, et al. A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998–2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis. 2011;53(8):e99-106.PubMedPubMedCentralCrossRef Feodoroff B, et al. A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998–2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis. 2011;53(8):e99-106.PubMedPubMedCentralCrossRef
49.
go back to reference Bolinger H, Kathariou S. The current state of macrolide resistance in Campylobacter spp.: trends and impacts of resistance mechanisms. Appl Environ Microbiol. 2017;83(12):e00416.PubMedPubMedCentralCrossRef Bolinger H, Kathariou S. The current state of macrolide resistance in Campylobacter spp.: trends and impacts of resistance mechanisms. Appl Environ Microbiol. 2017;83(12):e00416.PubMedPubMedCentralCrossRef
Metadata
Title
Bacteraemia, antimicrobial susceptibility and treatment among Campylobacter-associated hospitalisations in the Australian Capital Territory: a review
Authors
Cameron R. M. Moffatt
Karina J. Kennedy
Ben O’Neill
Linda Selvey
Martyn D. Kirk
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06558-x

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.